Eli Lilly, Novo Nordisk shares fall after Trump targets weight-loss drugs

** Shares of weight-loss drug developers Eli Lilly LLY.N and U.S.-listed shares of Novo Nordisk NOVOb.CO fall premarket

** Trump said prices of weight-loss drugs, such as Novo's Ozempic, would be lowered

** Lilly down 4.1% to $785.51, Novo falls 3.9% to $53.93; Novo's Denmark-listed shares down 6.3%

** J.P.Morgan says, "we see President Trump’s comments as in line with our expectations for the price negotiation related to Novo’s GLP-1 portfolio"

** YTD, up to last close, LLY up 6.1%, U.S.-listed Novo down 34.8%